The Company leads National Key R&D Plan of China in “Stem Cell Research and Organ Regeneration” and has developed multiple proprietary technology platforms, including the R-Clone Epithelial Stem Cell Cloning Platform, the IntelCell Intelligent Cell Platform, MIX0109 Tissue & Cell Rejuvenation Technology, Chimera Chimeric Animal Model Platform, REGEN-Wukong AI Platform, and Specialized Organ-Specific Validation Platforms. Leveraging these platforms, our company has built a pipeline of globally innovative regenerative medicine products.
REGEND001 is an innovative autologous lung progenitor cell therapy. In 2025, we completed the Phase II clinical trials in COPD and IPF indications, respectively. Phase I and Phase II clinical data of REGEND001 have demonstrated its potential to reverse disease progression in patients with COPD (impaired pulmonary diffusion function) and IPF, evidenced by regeneration of airway and alveolar tissue and significant improvement of lung function from multiple dimensions. Data from our first lung regeneration clinical trial were published in Science Translational Medicine and featured by Science at its homepage. Our lung progenitor cell therapy was featured as a drug development direction for COPD in the Nature Reviews Drug Discovery. REGEND001 was also granted Orphan Drug Designation from the FDA, supporting its future global development.
In May 2025, REGEND003, which is a kidney progenitor cell therapy for CKD, received IND approval from the NMPA and has since entered Phase I clinical trial. This drug candidate offers a potential fundamental approach to regenerate nephrons and treat renal failure. In March 2026, intra-renal transplantation of autologous kidney progenitor cells was successfully completed on the first enrolled patient in Phase I clinical trial, marking a historic milestone in regenerative medicine.
The commercial viability of our regenerative medicine approach was validated in 2025. On February 13, 2025, the “Airway Basal Stem Cell Therapy Technology for Chronic Obstructive Pulmonary Disease” project jointly submitted by us and Ruijin Hospital was officially approved as one of the first clinical translation projects in Hainan. Ruijin Hospital employs REGEND001 for the treatment of COPD, ILD (including IPF), and bronchiectasis patients. The therapy’s price, set at RMB150,000 per treatment, has been officially approved by the local medical insurance authorities, reflecting regulatory recognition of its clinical value and cost structure.
Our company is strongly supported by sustained capital investment. In 2023, we completed the Series B Investment and raised over RMB100 million, led by the SCGC Entities, one of China’s largest domestic investment firms. In early 2026, we raised over RMB340 million in the Series C Investment, marking one of the largest venture capital investments in China’s cell therapy sector.